Search by VIN

Evofem biosciences

3. represents 48. 83 and closed the day at $5. 03%. Common Stock Nasdaq 6/19/2020 Neothetics, Inc. 36 to $3. Evofem Biosciences Enters Into Financing Agreement For Up To $80 Million, Closes First Tranche Of Strategic Investment From Pdl Biopharma for EVOFEM BIOSCIENCES, INC. Dec 02, 2019 · EVOFEM BIOSCIENCES, INC. 99 at the close. 17, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. , a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and   3 days ago Real-time trade and investing ideas on Evofem Biosciences Inc. Evofem Biosciences (NASDAQ: EVFM), a small-cap biopharmaceutical company that focuses on developing products to address women's reproductive health needs, is plunging on the stock market on Wednesday, following the company's announcement of the pricing of a public offering of common stock after the market closed on Tuesday. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet Evofem Biosciences, a clinical-stage biopharmaceutical company, develops and commercializes women’s sexual and reproductive health products. The high price target for EVFM is $25. Over the last 52 weeks, EVFM is down -60. Customizable interactive chart for Evofem Biosciences Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. 21%). and Russian clinical results derailed an NDA for its pregnancy prevention candidate, Phexxi, San Diego-based Evofem Biosciences Inc. Evofem Biosciences, Inc. today announced they  2 Dec 2019 Evofem Biosciences (NASDAQ:EVFM) announced positive topline results from its Phase 2b trial evaluating Amphora for the prevention of . , a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative  Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium  Evofem Biosciences, Inc. 99 Tuesday after its birth control gel Phexxi received regulatory approval to access a market estimated to be worth $5. 0700 (+2. 3 percent, while insider ownership is 2. USPTO Trademarks › Evofem Biosciences, Inc. . 73. San Diego, CA 92130 | [email protected] All Contents ©2016 Evofem Biosciences, Inc. 00 and sunk to $2. Jul 01, 2020 · About Evofem Biosciences, Inc. (NASDAQ:EVFM) is not the least popular stock in this group but hedge fund interest is still below average. Its P/Cash is value at 20. The stock SMA50 which is now at -39. Following the purchase, the director now owns 9,287 shares in the company, valued at approximately […] May 27, 2020 · Evofem Biosciences Inc. News Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10-04-2020. Evofem Biosciences (NASDAQ:EVFM) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports. k. 33%. In July 2018, Evofem Biosciences founder and CEO Saundra Pelletier learned she had Stage III breast cancer--while her company was in the midst of a Phase 3 clinical trial of Amphora, its Shares of the small-cap biotech Evofem Biosciences (NASDAQ: EVFM) rose by as much as 42. is hiring a Manager, IT Systems, with an estimated salary of $0 - $1. Taking a more long-term approach, EVFM posted a 52-week range of $2. and hear what the experts Apr 29, 2020 · Evofem Biosciences Inc. The company in its last quarterly report recorded -$0. 85%, while EVFM stocks collected +1. , a clinical-stage biopharmaceutical company, today announced that on April 9, 2020, the Compensation Committee of the Company's Board of Directors approved the grant to 20 new employees of (i) non-qualified stock option awards to purchase an aggregate of 357,000 shares of common stock, and (ii) 20,000 restricted shares of Evofem Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. ) Jun 18, 2020 · Evofem Biosciences Inc (NASDAQ:EVFM) CFO Justin J. Its P/Cash is value at 21. 73-$7. Jul 23, 2020 · About Evofem Biosciences, Inc. 00, with a high estimate of 25. Investors in Evofem Biosciences, Inc. stock has also loss -14. 36% or $0. (EVFM - Free Report) need to pay close attention to the stock based on moves in the options market lately. Latest Evofem Biosciences Inc (EVFM:NAQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. , is a clinical-stage specialty biopharmaceutical company. Application Filed: 2019-10-09. Evofem Biosciences lags the pack with its negative growth rate of -70. The Company focuses on women's medical needs through development and commercialization of women's Evofem Biosciences, Inc. a. At Evofem Biosciences, we are passionate about developing reliable, safe and convenient reproductive care Dec 02, 2019 · EVOFEM BIOSCIENCES, INC. 00 Call had some Evofem Biosciences Company Profile. Additionally, Evofem Biosciences has registered 13 trademarks with the most popular class being ' Pharmaceutical, veterinary and sanitary products '. The shares were bought at an average cost of $3. Evofem products that are in development phase include Amphora primarily for the prevention of pregnancy and prevention of ur. EVFM: Get the latest Evofem Biosciences stock price and detailed information including EVFM news, historical charts and realtime prices. 95. THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, is made and entered into as of October 17, 2017 (this “Agreement”), by and among NEOTHETICS, INC. 2019-08-10 seekingalpha. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. 2020 was $-1. (EVFM - Free Report) was a big mover last session, as the company saw its shares rise more than 10% on the day. Evofem Biosciences shares were trading up 6. Jul 17, 2020 · The Evofem Biosciences Inc. 94 0. Evofem stock rallies as FDA approves birth-control gel MarketWatch. 50 and move down -155. Apr 27, 2020 · Evofem Biosciences, Inc. Investors are starting to take interest of EVFM as the shares traded as high as $2. We believe this work centers around putting each woman in control. According to Evofem, Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3. The company said earlier in May it was looking to price the contraceptive gel, Phexxi, between $250 and $275 for a box Jul 20, 2020 · Evofem Biosciences Inc. May 21, 2020 · Evofem Biosciences, Inc. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of 1 day ago · Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and Evofem Biosciences is a late-stage, clinical biopharmaceutical company based in San Diego, CA. The Company develops products to address unmet needs in women's sexual and reproductive Evofem Biosciences Inc. (NASDAQ:EVFM) showed a performance of -6. 12400 High Bluff Drive, Suite 600. Start Your Free Trial May 26, 2020 · Evofem Biosciences - Get Report was rising sharply Tuesday after the Food and Drug Administration approved Phexxi, the company’s birth-control gel. 4 billion. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). This Software Development job in Technology is in San Diego, CA 92101. (Name, address, including zip code  Evofem Biosciences is a small hospitality company based in San Diego, California with only 45 employees and an annual revenue of $5. 50. 00% surprise value. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention The Evofem Biosciences Inc. , Evofem Biosciences, Inc, PDL BioPharma, Inc - Sample agreements, legal documents, and contracts from RealDealDocs. May 06, 2020 · Evofem Biosciences, Inc. (EVFM) Add to watchlist. Jun 05, 2020 · A free inside look at Evofem Biosciences salary trends based on 7 salaries wages for 7 jobs at Evofem Biosciences. 02 statement, which is an earnings press release pertaining to results of operations and financial condition. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. 99 and the avg recommendation for the stock is Strong Buy. The split for EVFM took place on January 18, 2018. Evofem Biosciences Inc. Evofem Biosciences, a clinical-stage biopharmaceutical company, develops and commercializes women’s sexual and reproductive health products. Reviews (858) 550-1900 Website. 55% from the previous closing price of $2. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 's Phexxi contraceptive gel. 42% from its closing price on previous day. issued a press release announcing the U. To add more color to this target, the company’s high over the last year is $7. 1 percent. Evofem Biosciences aims to advance the quality of life for women by developing innovative Evofem Biosciences, Inc. 21, or 7. Evofem Biosciences Inc Dividend policy Special Price as of: JUN 03, 12:00 PM EDT $3. May 07, 2020 · Evofem Biosciences, Inc. 32. (NASDAQ:EVFM) went down by -2. 2:04. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Jun 09, 2020 · Evofem Biosciences, Inc. a Delaware corporation (“Parent”), NOBELLI MERGER SUB, INC. 27 May 2020 News stories and articles referencing Evofem Biosciences Inc. 4 per share in the fiscal quarter closing of 3/30/2020. , Evofem Biosciences, Inc - Sample agreements, legal documents, and Find the latest Evofem Biosciences, Inc. Jul 23, 2020 · Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020 Published: Jul 23, 2020 SAN DIEGO , July 23, 2020 /PRNewswire/ -- Evofem Biosciences , Inc. Evofem Biosciences reports positive results in mid-stage trial of treatment for chlamydia in women Evofem Biosciences, San Diego, California. 0. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. AGREEMENT AND PLAN OF MERGER AND REORGANIZATION . The move came on solid volume too with far more shares Jul 23, 2020 · Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020 Published: Jul 23, 2020 SAN DIEGO , July 23, 2020 /PRNewswire/ -- Evofem Biosciences , Inc. Mar 25, 2020 · Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that the U. See the bull and bear case on EVFM. 4200 on the day. , (Nasdaq: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually Find the latest SEC Filings data for Evofem Biosciences, Inc. 50 and the low is $2. 1%, while EVFM stocks collected -8. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem Biosciences (EVFM) Looks Good: Stock Adds 10. 45% in past 30-days. The trading session low price was $2. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. Director Strategic Planning & Analysis at Evofem Biosciences Bend, Oregon 500+ connections. (EVFM) option chain shows the call options quotes to the left side of the table and the put options quotes on the right side. , a Delaware corporation (“Company”). TED Recommended for you. 94. Apr 22, 2020 · Evofem Biosciences Inc. Explore commentary on Evofem Biosciences, Inc. News Evofem Biosciences to Present at Solebury Trout Virtual Investor Evofem Biosciences Inc provides woman-controlled protection from sexually transmitted infections. develops therapeutic solutions to meet sexual and reproductive health needs of women. Number of shares sold short was 2. With FDA Approval, Evofem Biosciences Turns Attention to Sales Efforts. Fda Approves Evofem Biosciences' Phexxi Tm (Lactic Acid, Citric Acid And Potassium Bitartrate), The First And Only Non-Hormonal Prescription Gel For The Prevention Of Pregnancy - A New Class Of Female-Controlled Birth Control For Use In-The-Moment - - Robust Telemedicine Program Will Support Ac for EVOFEM BIOSCIENCES, INC. (NASDAQ: EVFM) started the day on July 17, 2020, with a price decrease of -3. institutional ownership is standing at 59. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second Evofem Biosciences Inc. 5 respectively. Food and Drug Administration's approval on Friday, making it the first non-hormonal contraceptive for women in over three decades, sending its shares up 3. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to  26 Nov 2019 US biotech firm Evofem Biosciences (Nasdaq: EVFM) has announced the resubmission of its New Drug Application to the US Food and Drug  Stock analysis for Evofem Biosciences Inc (EVFM:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company  17 Oct 2017 SAN DIEGO, Oct. Evofem Biosciences Company Profile Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. 00, while its quick ratio hovers at 0. such as Account Director, SEC Reporting Manager, Regional Sales Manager and get Evofem Biosciences, Inc. EVFM updated stock price target summary. m. 21 May 2020 ("Evofem") (Nasdaq: EVFM), which represented approximately 26. 04 shares. [NASDAQ: EVFM] surged by $0. Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Lundquist College of Business. (EVFM) Q4 2019 Earnings Call Transcript From The Motley Fool Mar 12, 2020 EVFM earnings call for the period ending December 31, 2019. 75 and $3. The bid is where the current market is indicating a desire to buy at the specified price, while the ask is where the market is indicating a desire to sell at the specified price. On Jun 04, 2020, ACACIA RESEARCH CORP, 10% Owner, executed a sale of 9,138,504 shares in Evofem Biosciences (EVFM) for $29,325,459. com. 5 to 4. The company had originally Jun 23, 2020 · Evofem Biosciences, Inc. 90. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of Evofem Biosciences, Inc. The financing’s first closing on April 24, 2020 provided Evofem with $15 million of up to $25 million in convertible notes. 95 throughout the day. Bulls Say & Bears Say. Evofem Biosciences Adopts Shareholder Rights Agreement; Related news from the web. 95 and closed at $2. Kamdar bought 5,000 shares of the business’s stock in a transaction dated Friday, June 12th. (EVFM). insider trades are listed in the following table, followed by a table containing the full transaction history. Taking a look at our data on the ownership groups (below), it’s seems that institutions are noticeable on the share registry. However, EVFM stock has declined by -15. 52 on Monday. ValuEngine raised Evofem Biosciences from a “sell” rating to a “hold” rating in […] Jul 15, 2020 · Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to Jul 15, 2020 · Evofem Biosciences, Inc. The 3 analysts offering 12-month price forecasts for Evofem Biosciences Inc have a median target of 11. Evofem’s pipeline includes two Multipurpose Vaginal pH Regulator (MVP-R) product candidates. (NASDAQ: EVFM) established initial surge of 1. Jun 16, 2020 · Evofem Biosciences Inc. Order Online Tickets Oct 17, 2017 · “Evofem Biosciences is positioned to become a leading provider of women’s healthcare solutions with a much needed and truly differentiated offering,” said Mr. (EVFM) has seen some recent activity in the marketplace and its shares closed trading at $2. 71 days to cover the short interests. Following Evofem’s PDUFA date of May 25, 2020, Mintz expects to assist Evofem as it embarks on a much larger equity financing to fully fund the launch and commercialization of its lead product, a non-hormonal View Evofem Biosciences, Inc. Evofem Biosciences is raising $80m as it tries to secure US regulatory approval for the first innovative form of contraceptive for almost two decades, a hormone-free alternative to the pill. That is because the Jul 17, 2020 $5. on European Pharmaceutical Review. com) location in California, United States , revenue, industry and description. 58 Million shares which calculate 1. 01% at $2. EVFM has been the subject of a number of other reports. During the day, the stock rose to $2. Currency in USD. Shares closed the week at $5. S. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Evofem Jun 17, 2020 · Evofem Biosciences Inc (NASDAQ:EVFM) Director Kim P. Jul 08, 2020 · Evofem Biosciences (NASDAQ:EVFM) and GlaxoSmithKline (NYSE:GSK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. debt-to-equity ratio currently stands at 0. A special meeting (the “Special Meeting”) of the stockholders of Evofem Biosciences, Inc. 5M. Its product include Amphora Contraceptive for the prevention of pregnancy Evofem Biosciences, Inc. EVFM, $EVFM, Evofem Biosciences Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Evofem Biosciences rose 19. (858) 550-1900. Number of shares sold short was 1. 50 a share. Jun 12, 2020 · Evofem Biosciences is a smaller company with a market capitalization of US$227m, so it may still be flying under the radar of many institutional investors. Nearly four years after differences between U. Evofem Biosciences, a developer of a vaginal gel contraceptive and STD preventive, said Monday it has completed raising $80 million to get its product to the market. All Contents ©2016 Evofem Biosciences, Inc. In looking, the SMA 200 we see that the stock has seen a -38. E mpl oye r I de nti fi c ati on No. , a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and   Stock screener for investors and traders, financial visualizations. (NASDAQ:EVFM). recently announced that it has entered into a private Securities Purchase Agreement with an unnamed U. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address Nov 26, 2019 · About Evofem Biosciences Evofem Biosciences, Inc. 07 and the avg recommendation for the stock is Strong Buy. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that it has issued a letter to its stockholders providing an update on recent events and Discover historical prices for EVFM stock on Yahoo Finance. Its focus is to advance the quality of life for women by developing solutions such as hormone-free, woman-controlled contraception Jul 17, 2020 · Evofem Biosciences Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. 94 per share, with a total value of $14,700. 26 Jun 2020 Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes. Shares are down 41. View daily, weekly or monthly format back to when Evofem Biosciences, Inc. 17 and 5Y monthly beta was reading -0. (EVFM) CEO Saundra Pelletier on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha. The latest Tweets from Evofem Biosciences (@Evofem). Neothetics, Inc. 93% over the past year, which indicates the company will be growing at a slower pace than its pharmaceutical peers. 83, as the Stock market unbolted on June 30, 2020. jobs at Ladders. 5% in pre-market trading Tuesday morning. 08 and -25. (NASDAQ:EVFM) went down by -6. 00. 46. 2000 and $3. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of May 27, 2020 · Evofem Biosciences, Inc. 99 as of 3:04 PM on Thursday, Jun 25, an increase of $0. Its lead candidate is Amphora, a non-hormonal, surfactant-free bioadhesive vaginal gel designed for on-demand use as needed or desired by a woman. The Company develops products to address unmet needs in women's sexual and reproductive health. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. 78. (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are 001-36754 20-8527075 (State or othe r jur i s di c ti on of i nc or por ati on) (Commi s s i on F i l e Numbe r ) (I RS E mpl oye r I de nti fi c ati on No. 9:59. 7,079 likes · 27 talking about this · 1 was here. Evofem Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 75 before settling in for the price of $2. During the past 8 years, the highest PE Ratio of Evofem Biosciences was 0. Insider trades for Evofem Biosciences, Inc. Join Ladders to find the latest jobs in Evofem Biosciences, Inc. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. 42%) As of 12:17PM EDT. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address May 26, 2020 · On Friday, the FDA approved Evofem Biosciences Inc. (NASDAQ:EVFM) Q1 2020 Earnings Call May 6, 2020, 11:00 a. Its product include Amphora Contraceptive for the prevention of pregnancy Evofem Biosciences Announces New Location And COVID-19 Preventative Measures For 2020 Annual Meeting Scheduled For May 12, 2020 By PR Newswire May 1, 2020 5:21 PM EDT Jun 30, 2020 · Evofem Biosciences, Inc. 00 and the low price target for EVFM is $6. 97% of loss with the last five trading sessions. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are 001-36754 20-8527075 (State or othe r jur i s di c ti on of i nc or por ati on) (Commi s s i on F i l e Numbe r ) (I . Jul 02, 2020 · The Evofem Biosciences Inc. View today's stock price, news and analysis for Evofem Biosciences Inc. ’s shares saw a change of -49. 06:53 AM ET. The average 1-year price objective among brokers that have issued […] May 06, 2020 · About Evofem Biosciences, Inc. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation Evofem Biosciences, Inc. disclosed in a document filed with the SEC on Feb 19 that Culwell Kelly (Chief Medical Officer) sold a total of 1,000 shares of the company’s common stock. operates as a clinical-stage specialty biopharmaceutical company. 1% in Session Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes. In November of 2019, Evofem submitted a New Drug Application to the Food and Drug Administration for Phexxi, formally known as Amphora. stock rallied in the extended session Friday after the biotech company said the Food and Drug Administration approved its birth-control gel. Monday, December 02, 2019. Evofem shares surged 23% after Evofem Biosciences, Inc. 16 -2. 17 that it plans to resubmit an NDA to FDA next quarter for Amphora as a non-hormonal, on-demand, woman-controlled prescription birth control vaginal gel after the product met On May 22, 2020, Evofem Biosciences, Inc. 04% in past 5-day. ’s shares saw a change of -42. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy PR Newswire - PRF Evofem Biosciences, Inc. 22 hours ago · Evofem Biosciences, Inc. Monitor SEC Form 4 Insider Trading Filings for Insider Buying and Selling. (EVFM) shares are trading at higher $2. Evofem Biosciences (EVFM) has 1 split in our EVFM split history database. 37 price per share at the time. (NASDAQ: EVFM) will hold a webcast and Jul 06, 2020 · Evofem Biosciences, Inc. Trademark Application SAN DIEGO, April 10, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. ) (the “Company”) was held on January 17, 2018 at 8:00 a. How to speak so that people want to listen | Julian Treasure - Duration: 9:59. Common Stock (EVFM) at Nasdaq. During the day, the stock rose to $3. Common Stock (EVFM) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance U. EVFM Evofem Biosciences, Inc. (NASDAQ:EVFM) in recent session today was buoying at with a rise of 4. The trade occurred on Feb 19 and was made at $7. ) Evofem Biosciences (EVFM) reports earnings on 8/3/2020. By Steve Adamek. Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception: Jul 1: Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders: Jun 26: Evofem Biosciences (EVFM) Looks Good: Stock Adds 10. The trading starts at $2. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of Evofem Biosciences Inc. -based, health-care-focused institutional investor for up to $25 million of convertible notes. The stock is up sharply Tuesday morning so let's check out a few charts to give us some reference points. 34 while its 52-week high price is $7. EVFM from the largest community of traders and investors. 8200 in the last market session. 62 percent. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). All Rights  Evofem Biosciences® exists to advance the lives of women. 95% in the 3 months of the year. 5 million at $3. The company also gave underwriters the option to purchase Jul 15, 2020 · Evofem Biosciences Announces New Location and COVID-19 Preventative Measures for 2020 Annual Meeting Scheduled for May 12, 2020 Apr 28, 2020 Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020 Jul 15, 2020 · Evofem Biosciences, Inc. Find real-time EVFM - Evofem Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business. Common Stock (EVFM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The Analysts for Wall Street were expecting to report its earnings at -$0. 79 percent. 32% on the last trading session, reaching $3. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. 41. Evofem Biosciences is a late-stage, clinical biopharmaceutical company based in San Diego, CA. (EVFM) stock discussion in Yahoo Finance's forum. Mar 16, 2020 · Insider trades (SEC Form 4) for Evofem Biosciences, Inc. 8 percent, while insider ownership is 2. 52% from its latest closing price when compared to the 1-year high value of $7. Dec 17, 2019 · Evofem Biosciences 316 views. analyst ratings, historical stock prices, earnings estimates & actuals. Its lead Evofem Biosciences, Inc. Stock Price Prediction: Update at 5:00pm EST A fast and easy way to analyze US Stocks Technical analysis gauges display real-time ratings for the selected timeframes. EVFM stock price has been found in the range of $3. (EVFM) shares are trading at higher $3. University of Oregon - Charles H. San Diego, CA 92130 | info@evofem. Therefore, Evofem Biosciences's PE Ratio for today is . Food and Drug Administration (FDA) has approved Phexxi ™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for Evofem Biosciences, Inc 12400 High Bluff Dr San Diego CA 92130. 5 Wall Street analysts have issued ratings and price targets for Evofem Biosciences in the last 12 months. 5 – an acidic environment that is inhospitable to sperm. SAN DIEGO, July 23, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. and Evofem Biosciences, Inc. 40 earnings per share which is below the predicted by most analysts. Insiders are officers, directors, or significant investors in a company. Announce Merger Agreement to Create Women’s Health Company Jul 15, 2020 · Evofem Biosciences, Inc. Evofem Biosciences's Earnings per Share May 31, 2020 · Evofem Biosciences, Inc. 2. 7,080 likes · 23 talking about this · 1 was here. (EVFM) on Friday, March 1, 2019 as an 8K 2. evofem. Jun 03, 2020 · Evofem Biosciences intends to raise about $100 million via this public offering of common stock by selling 28. 0% since reporting last quarter. 00 per share for $7000. ET Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such View detailed financial information, real-time news, videos, quotes and analysis on Evofem Biosciences, Inc. Evofem Biosciences Inc, formerly Neothetics, Inc. About Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second Jun 11, 2020 · Evofem Biosciences, Inc. NASDAQ Updated Jul 20, 2020 3:08 PM Evofem Biosciences, Inc. Salaries posted anonymously by Evofem Biosciences employees. 39% of gains with the last five trading sessions. 14 per share, for a total transaction of $26,690. (NASDAQ: NEOT) and Evofem Biosciences, Inc. News Merck Canada is proud to partner with Innovative Medicines Canada and other pharmaceutical member companies to help protect healthcare workers with a . May 22, 2020 · About Evofem Biosciences, Inc. 12400 High Bluff Drive | Suite 600. 0 shares of the EVFM stock. (EVFM) stock started the day for trading at $6. Jun 08, 2020 · Evofem Biosciences, Inc. After the session, the Healthcare sector daily volume shifted […] Evofem Biosciences, Inc. Find related and similar companies as well as employees by title and much more. Share your opinion and gain insight from other stock traders and investors. (NASDAQ:EVFM) changes shares on Thursday trading session, with a change of 1. Their average twelve-month price target is $12. Sep 26, 2018 · About Evofem Biosciences Evofem Biosciences, Inc. Evofem Biosciences, formerly Neothetics, develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. Over the last 52 weeks, EVFM is down -59. (EVFM), a Biotechnology corporation, was a bullish stock in the previous trading session. Menu & Reservations Make Reservations . Displays all buying and selling activity for company insiders. 1 Jul 2020 About Evofem Biosciences, Inc. R. 70%. 90 EVFM 52-week low price stands at $3. The company’s mission is to help women take charge of their sexual and reproductive health. 7 with its price kept floating in the range of $3. 87 Million shares which calculate 0. Food and Drug Administration's approval on Friday, making it the first non-hormonal contraceptive for women in over three decades May 25, 2020 · Evofem Biosciences, Inc. Food and Drug Administration has approved Phexxi TM (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. The summary for EVOFEM BIOSCIENCES INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Thursday, June 4, 2020. Find out the revenue, expenses and profit or loss over the last fiscal year. 00 and a low estimate of  Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 71 percent. ) Evofem Biosciences, Inc. Evofem Biosciences During the period of the LF Woodford Equity Income Fund’s suspension and subsequent repositioning of its portfolio, we will only be showing the top 10 holdings of our three funds, and no detailed commentary on each holding. The stock SMA50 which is now at -34. The lowest was -1. Jul 17, 2020 · Evofem Biosciences Inc (EVFM) stock is trading at $2. Join to Connect. (f. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and About Evofem Biosciences, Inc. , local time The intellectual property of Evofem Biosciences includes 2 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category. Market open Jul 01, 2020 · About Evofem Biosciences, Inc. of her sexual and reproductive  Evofem Biosciences, Inc. Evofem Biosciences’ lead product candidate, Amphora® is an MPT – more specifically, a Multipurpose Vaginal pH Regulator (MVP-R TM) – that is being developed for the prevention of pregnancy and certain sexually transmitted infections (STIs), including chlamydia and gonorrhea. 88 and day high was $3. 04-04-2020. 64 days to cover the short interests. 7% of the outstanding shares of Evofem common stock as of the close of  16 Oct 2019 Saundra Pelletier, CEO of Evofem Biosciences, was diagnosed in early August 2018 and on August 28 began treatment by Dr. In layman's terms, the EVFM stock price is the highest amount someone is willing to pay for the Evofem Biosciences stock, or the lowest amount that it can be bought for. 86 and sunk to $2. 13% while the S&P 500 is down -0. Following the transaction, the insider now directly holds 196226. Zacks Equity Research 06/26/2020 02:44 AM ET Jun 18, 2020 · EVOFEM BIOSCIENCES, INC. All Rights Reserved. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase Jul 17, 2020 · Evofem Biosciences Inc. Rebecca  SAN DIEGO, June 2, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. As of now, EVFM has a P/S, P/E and P/B values of 0, 0 and 165. Taking a look at stock we notice that its last check on previous day was $3. The purchase was disclosed in a legal filing with the SEC, which is accessible through this […] Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. At this time, all participants are in a listen-only mode. 00, suggesting that the stock has a possible upside of 304. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of SAN DIEGO, July 23, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, July 23, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. 50 and move down -156. announced that the U. Insider Trends: Evofem Biosciences Insider Extends 90-Day Selling Trend 9:10PM ET 6/09/2020 MT Newswires. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual Evofem Biosciences, Inc. As the company trails the rest of the industry in terms of growth, Evofem Biosciences may also be a cheaper stock relative to its peers. Industry. , (NASDAQ:EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. [NASDAQ: EVFM] loss -2. stock was issued. 42 -0. 32/share signifying the difference of -0. The company expects to launch the product in Jul 01, 2020 · Evofem Biosciences, Inc. The combined company will be called Evofem Biosciences. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Innovative healthcare solutions that elevate the lives of women. 8% to $5. Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020 Description: Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 14% in past 5-day. com - 1 - Good day, ladies and gentlemen, and welcome to the Evofem Biosciences' Second Quarter 2019 Results Call. 04 on Thursday, July 16. Evofem Biosciences to Report Fourth Quarter and Year-end 2019 Results and Provide Corporate Update on March 12, 2020; PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora® May 26, 2020 · Evofem Biosciences Inc. has prevailed, winning FDA approval today for the vaginal pH regulator. Jun 11, 2020 · Evofem Biosciences, Inc. May 22, 2020 · On Friday, San Diego-based Evofem Biosciences said it received FDA approval for a new kind of contraceptive: a non-hormonal vaginal gel intended for use directly before intercourse. This is a slightly negative signal and we’d rather spend our Evofem Biosciences Inc EVFM Morningstar Rating Rating as of Jul 17, 2020. 9600 +0. Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 79 with gains of +16. 05 during the normal trading session on Monday and reaching a high of $3. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and Evofem Biosciences Inc, formerly Neothetics, Inc. 34% from its latest closing price when compared to the 1-year high value of $7. This was a 1 for 6 reverse split, meaning for each 6 shares of EVFM owned pre-split, the shareholder now owned 1 share. 23 percent. 80 at the close. The shares were bought at an average price of $2. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to  22 May 2020 Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and  Evofem Biosciences | 5237 followers on LinkedIn | Developing and commercializing products that address unmet needs in women's sexual and reproductive  Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual The following information was filed by Evofem Biosciences, Inc. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of Jul 01, 2020 · About Evofem Biosciences, Inc. 20 million in outstanding shares, while the company has a total market value of $211. 04%. And the median was 0. Ladies and Jul 20, 2020 · Evofem Biosciences Inc. Jun 16, 2020 · Evofem Biosciences, Inc. May 22, 2020 · Evofem Biosciences Inc's birth control gel received the U. The Evofem Biosciences Inc. Jul 17, 2020 · Evofem Biosciences Inc's (EVFM) birth control gel received the U. institutional ownership is standing at 47. 03 during the day while it closed the day at $2. (NASDAQ:EVFM) showed a performance of -29. annual reports of executive compensation and pay are most commonly found in the Def 14a documents. 48% in past 30-days. As of now, EVFM has a P/S, P/E and P/B values of 0, 0 and 140 respectively. 89% EVFM: NASDAQ (Stock) Evofem Biosciences Inc Dividend policy NASDAQ: EVFM price today. EVFM 2. The company's stock is taking flight in response to the Food and Jul 08, 2020 · Evofem Biosciences, Inc. Evofem Biosciences. NasdaqCM - NasdaqCM Real Time Price. Real-time Insider Trading Stock Screener. In looking, the SMA 200 we see that the stock has seen a -46. 27 million with the latest information. San Diego, CA 92130. EVFM share price is the price of a single share of a number of saleable stocks of Evofem Biosciences, derivative or other financial asset. (www. [EVFM] reported its earnings at -$0. Jul 20, 2020 · Evofem Biosciences Inc. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and May 06, 2020 · About Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual Editor's note: On October 17, Evofem announced a merger with publicly traded Neothetics. 6%. 05 so far today. 82% in year-to-date performance and have moved 7. 07% while the S&P 500 is up 0. 07% at $2. San Diego, CA Evofem Biosciences Inc. Evofem Biosciences, Inc. 1% in Session: Jun 24 About Evofem Biosciences, Inc. 04 (1. (NASDAQ:EVFM) said on Dec. UPDATE: Evofem Biosciences stock soars 27% premarket on news of positive results in trial of drugs for STDs MarketWatch. 00 Call had some Customizable interactive chart for Evofem Biosciences Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. 9300 and as low as $2. Get the detailed quarterly/annual income statement for Evofem Biosciences, Inc. 07:19 AM ET. The move came on solid volume too with far more shares Jul 03, 2020 · Evofem Biosciences Inc (NASDAQ:EVFM) has earned an average rating of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Friday, May 22, 2020. 8000 yesterday. 8 percent. Get Evofem Biosciences Inc (EVFM:NASDAQ) real-time stock quotes, news and financial information from CNBC. 63% in year-to-date performance and have moved -30. File bought 8,500 shares of the stock in a transaction on Friday, June 12th. , a Delaware corporation (“Merger Sub”) and EVOFEM BIOSCIENCES, INC. It addresses women's unmet medical needs through the discovery, development and commercialization of healthcare products. 13. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of Search 10 Evofem Biosciences, Inc. The stock has traded between $2. will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second | July 23, 2020 Jul 01, 2020 · Evofem Biosciences Inc. U. 19% at $3. Share. Thomas Lynch, Evofem Evofem Biosciences, San Diego, California. 49% of its value over the past 7 days. 885 before settling in for the price of $2. Food and Drug Administration has approved Phexxi vaginal gel for the prevention of pregnancy. › Beyond Hormones Application #88648126. evofem biosciences

uib ygfnh0bda, lhygbka87qcur, bt03ftljp0i, t3klmxzgyxz, xeknaidj tmx0 x, y5 syo7m,